Eli Lilly and Novo Nordisk Outlook: Analyzing Growth Potential in the Weight-Loss Drug Market through 2027
Eli Lilly (LLY) and Novo Nordisk (NVO) continue to dominate the rapidly expanding weight-loss drug market, though they have experienced divergent stock performances over the past year. Eli Lilly has seen significant momentum with a 41% share price increase, driven by strong revenue growth in its GLP-1 products Mounjaro and Zepbound. The company is also preparing for a regulatory filing for its next-generation medicine, retatrutide, in early 2027. Conversely, Novo Nordisk has faced recent headwinds with a 15% drop in share price, despite reporting third-quarter net sales growth of 6%. The company's recovery is being bolstered by the success of oral Wegovy, which is attracting new patients rather than merely cannibalizing existing product lines. Both companies face potential risks from increased competition in the obesity sector and clinical or regulatory hurdles for their upcoming drug candidates.

Topics: GLP-1 Pharmaceuticals Quarterly Earnings Weight Loss Drugs
Read the full article at Motley Fool
Part of the story Novo Nordisk reports liver improvements with Wegovy in some patients (4 articles)